Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01154426

Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies

Study identifier: NCT01154426
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Solid tumor with progressive disease following therapy or for which acceptable standard treatment does not exist
  • No more than 2 prior chemotherapeutic regimens
  • Must have a known BRCA mutation or willingness to undergo BRCA mutation analysis
  • No prior PARP inhibitor treatment

Type of study:

Phase I study

Treatment:

21-day cycles where participants receive veliparib twice daily on days 1-14 and gemcitabine hydrochloride IV on days 1, 8, and 15

Study sites:

Pennsylvania
Hershey
Penn State Milton S Hershey Medical Center
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu

Pittsburgh
University of Pittsburgh Cancer Institute
Contact: Edward Chu 412-623-5898 chue2@upmc.edu

Magee-Womens Hospital - University of Pittsburgh Medical Center
Contact: Robert P. Edwards redwards@mail.magee.edu

UPMC Hillman Cancer Center
Contact: Adam M. Brufsky brufskyam@upmc.edu

Page updated 06/13/13